GlassScriptPhysician profile
John Eb Fugate
NPI 1902971419
$3,143.34
in general payments reported to CMS, 2019-2025
18 companies · $498 in 2025
The $498 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.46 · 2020: $40.19 · 2021: $652 · 2022: $667 · 2023: $598 · 2024: $597 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.43 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $740.74 | 2019-2025 | Cequa, Xelpros |
| Alcon Vision LLC | $345.75 | 2021-2025 | Clareon, Tryptyr, Hydrus Microstent |
| Coopervision INC. | $306.55 | 2020-2025 | Myday Contact Lens, Clariti Contact Lens |
| Abbvie INC. | $283.40 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $244.85 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Allergan, INC. | $228.92 | 2021-2022 | |
| Dompe US, INC. | $160.16 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $156.10 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $129.07 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $119.90 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $94.50 | 2024 | Acuvue |
| Novartis Pharmaceuticals Corporation | $86.47 | 2019-2022 | |
| Biotissue Holdings INC. | $70.25 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $60.60 | 2022 | |
| Kala Pharmaceuticals, INC. | $47.60 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $38.14 | 2025 | Idosetr |
| Amgen INC. | $16.61 | 2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fugate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.